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Abstract
Cardiovascular disease (CVD) accounted for 27% of all deaths in the United Kingdom in
2014, and was responsible for 1.7 million hospital  admissions in 2013/14. This condition
becomes increasingly prevalent with age, affecting 34.1 and 29.8% of males and females over
75 years of age respectively in 2011. The dysregulation of cholesterol metabolism with age,
often observed as a rise in low density lipoprotein cholesterol (LDL-C), has been associated
with the pathogenesis of CVD. To compound this problem, it is estimated by 2050, 22% of
the world’s population will be over 60 years of age, in culmination with a growing resistance
and intolerance to pre-existing cholesterol regulating drugs such as statins. Therefore, it is
apparent research into additional therapies for hypercholesterolaemia and CVD prevention is
a  growing necessity.  However,  it  is  also imperative  to  recognise  this  complex biological
system cannot  be  studied  using  a  reductionist  approach;  rather  its  biological  uniqueness
necessitates a more integrated methodology, such as that offered by systems biology. In this
review we firstly discuss cholesterol metabolism and how it is affected by diet and the ageing
process. Next, we describe therapeutic strategies for hypercholesterolaemia, and finally how
the  systems  biology  paradigm  can  be  utilised  to  investigate  how  ageing  interacts  with
complex systems such as cholesterol metabolism.
Introduction
Life expectancy has increased dramatically (Figure 1). In the UK, males and females born in
1982, had a life expectancy of 71.1 and 77.0 years respectively, while the projected values for
2082 are 89.7 and 92.6 years(1). Thus, we are witnessing a staggering demographic shift in
favour  of  older  people  (Figure 2). For instance,  it  has  been estimated  the  percentage  of
individuals in the UK over 60 years of age will double to 22% by 2050, when compared to
2000(2).  Remaining  disease  free  is  a  significant  challenge  faced  by  older  people,  as  the
prevalence of many conditions increases with age (Figure 3). Of the diseases associated with
advancing age, CVD is the leading cause of morbidity in individuals over 60 years of age (3).
The dysregulation of cholesterol metabolism is intimately associated with the pathogenesis of
CVD(4),  and age-related alterations  in the metabolism of cholesterol  are implicated  in the
disturbance  of  this  system(5).  These  include,  a  decrease  in  LDL-C clearance;  a  potential
increase  in  cholesterol  absorption;  a  decrease  in  bile  acid  synthesis;  and  a  decrease  in
bacterial  bile  acid  modification(6;  7;  8).  It  is  likely  these  alterations  play  a  role  in  the
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accumulation of LDL-C, and disease pathogenesis. The accumulation of plasma cholesterol
can also be moderated by diet, while pharmaceutical and pre- and probiotic administration
have largely been associated with reduced LDL-C levels and CVD risk(9; 10; 11; 12; 13). 
Traditionally,  when  nutritionists  have  investigated  complex  metabolic  pathways,  such  as
cholesterol metabolism, they have utilised conventional wet laboratory techniques. However,
studying  cholesterol  metabolism  and  its  interaction  with  both  diet  and  ageing  using
conventional approaches is challenging, due to the integrated nature of this system, and the
time scales involved in studying the effects of the ageing process. Traditional  in vivo or in
vitro techniques can also be limited when testing a hypothesis, as such approaches can be
resource-intensive, expensive, impractical and potentially unethical(14). Thus, utilisation of the
systems  biology  approach  is  becoming  an  increasingly  important  tool  in  nutrition  based
research, as systems biology overcomes a number of the challenges outlined above, but more
importantly, facilitates the integration of data generated from a diverse range of sources (14),
leading to an improved understanding of how cellular dynamics influence the behaviour of
tissues  and  ultimately  the  health  of  whole  organ  systems(15).  Thus,  the  systems  biology
approach seeks to understand complex biological systems by studying them in a more holistic
manner, in contrast to the reductionist approach regularly adopted in human nutrition. At the
core of the systems biology approach is computational modelling. Computational modelling
is an abstract process that is used to represent the dynamics of a biological system in a precise
manner  using  mathematics.  The  steps  involved  in  building  a  computational  model  are
outlined  in  Figure  4.  Computational  models  are  now used  to  model  a  diverse  range  of
complex nutrient centred pathways including cholesterol metabolism for a number of reasons.
Firstly, computational models are capable of providing quantitative data on the interaction of
molecular components(16). Secondly, nutrient-based interactions are inherently complex and
often  non-linear  in  nature(17;  18;  19),  and  can  involve  complex  feedback  and  feed-forward
loops(20;  21;  22). Thus, it is challenging and even unfeasible to reason about these by human
intuition  alone.  Computational  modelling  offers  an  alternative  means  of  handling  this
complexity,  thus  utilisation  of  computational  modelling  alongside  experimental  work
provides a means of representing the dynamics of complex biological systems. Models can be
used to simulate intrinsic perturbations, such as those associated with ageing and extrinsic
perturbations,  such  as  diet.  Output  from the  model  provides  an  overview  of  how  these
changes impact the dynamics of the system, and the implications this has for health-span. In
this  review  we  present  an  overview  of  cholesterol  metabolism  and  discuss  how  ageing
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impacts  its  regulatory  mechanisms.  We  also  discuss  how  diet  influences  cholesterol
metabolism, and how the dysregulation of this system influences heath.  Next,  we discuss
therapeutic  strategies  for  the  treatment  of  hypercholesterolaemia,  namely  dietary,
pharmacological,  and  probiotic  intervention.  Finally,  we  describe  how  we  are  using  the
systems biology framework to investigate cholesterol metabolism and the impact ageing has
on it. Specifically, there is a focus on how we have used computational modelling and how
we are exploring this approach with simulated digestive tracks. 
Overview of Cholesterol Metabolism
Cholesterol plays a vital role in the body as a component of cell membranes, and precursor to
steroid  hormones  and bile  acids.  Whole  body cholesterol  metabolism is  encapsulated  by
cholesterol  ingestion,  absorption,  excretion  and  synthesis.  These  factors  interact  in  a
coordinated  fashion  to  regulate  whole-body  cholesterol  balance,  with  subtle  changes  to
individual components influencing the behaviour of the others, so that cholesterol balance is
maintained.  In  the  next  sections  we will  outline  in  detail  the complexities  of  cholesterol
metabolism and how ageing interacts with it, thus emphasising the need for a systems biology
approach when investigating it. 
Cholesterol Ingestion and Absorption
In the UK, the average daily intake of cholesterol is 304 and 213mg for males and females
respectively(23); 10-15% of which is in the esterified form(24). In the small intestine, esterified
cholesterol is hydrolysed to form free cholesterol, which is more readily incorporated into
bile acid micelles, which facilitate the absorption of cholesterol via Niemann-Pick C1-Like 1
protein  (NPC1L1)(25;  26).  Additionally,  phytosterols  can  also  be  absorbed  via  NPC1L1(27).
Intestinal  absorption of  cholesterol  and phytosterols  can be limited  by heterodimer  ATP-
binding cassette (ABC) G5/G8, which effluxes these sterols back to the intestinal lumen(28).
Acyl coenzyme A: cholesterol acyltransferase 2 (ACAT-2) esterifies internalised cholesterol,
which is then incorporated into a nascent chylomicron via microsomal triglyceride transfer
protein (MTP)(29; 30). The nascent chylomicron then exits the enterocyte by exocytosis into the
lymphatic system before entering the blood stream(31). The nascent chylomicron is converted
to  a  mature  chylomicron upon acquisition  of  apolipoprotein  (apo)  C-II  and E from high
density  lipoproteins  (HDL).  Apo C-II  activates  lipoprotein  lipase  (LPL)  on  the  capillary
endothelium  of  adipose  or  muscle  tissue,  which  in  turn  catalyses  the  hydrolysis  of
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triacylglycerol  (TAG)(32;  33).  Apo  C-II  is  then  returned  to  HDL,  and  hepatic  low density
lipoprotein receptors (LDLr) and LDL receptor-related protein (LRP) recognise apo B-48 and
E, initiating the absorption of the chylomicron remnants(34). 
Cholesterol Synthesis
Cholesterol is synthesised endogenously in all nucleated cells in the body from acetyl CoA(35).
Renfurm  et  al.  (2004)  observed  endogenous  cholesterol  was  synthesised  at  a  rate  of
9.8±6.2mg/kg/day in healthy adults with a mean age of 32 years and mean weight of 64kg(36).
This equates to 627.2mg/day of synthesised cholesterol, a similar value to the 710mg/day
observed by Jones and Schoeller (1990). Interestingly, cholesterol consumption can influence
the  synthesis  of  endogenous  cholesterol;  an  increase  from 173  to  781mg/day  of  dietary
cholesterol has been observed to decrease the rate of sterol synthesis by 34%(37).
Cholesterol  synthesis  commences  when  acetoacetyl  CoA  thiolase  catalyses  the
interconversion of acetyl CoA and acetoacetyl CoA. One molecule of acetyl CoA and one
molecule acetoacetyl CoA undergo a condensation reaction by 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG CoA) synthase to form a molecule of HMG CoA. HMG CoA reductase,
with the addition of 2 nicotinamide adenine dinucleotide phosphate (NADPH) molecules,
then catalyse the conversion of HMG CoA to mevalonate. As the rate limiting enzyme of
cholesterol  biosynthesis,  HMG CoA reductase  is  the therapeutic  target  of  statins,  for  the
treatment of hypercholesterolaemia, and the prevention of atherosclerosis(38). Phosphorylation
of  mevalonate  by the enzyme mevalonate  kinase forms mevalonate-5P,  which  undergoes
further phosphorylation to form mevalonate-5PP via the enzyme phosphomevalonate kinase.
Decarboxylation and dehydration by mevalonate-5PP decarboxylase creates isopentenyl-PP
(IPP),  and thus  its  isoform dimethylallyl-PP (DMAPP) via  isopentenyl  diphosphate  delta
isomerase.  Farnesyl  diphosphate  synthase initiates  the condensation of  DMAPP with one
molecule of IPP and NADPH to create geranyl-PP. Further condensation and the addition of
another molecule of IPP and NADPH creates farnesyl-PP. Condensation of 2 farnesyl-PP
molecules by squalene synthase and NADPH forms squalene,  which is then converted to
squalene epoxide by squalene epoxidase, NADPH, and O2, before undergoing cyclisation by
oxidosqualene cyclase to form lanosterol(39). A series of reactions, including the branching of
7-dehydrodesmosterol to either desmosterol or 7-dehydrocholesterol, both of which can then
be converted to the end product cholesterol via the enzymes 24-dehydrocholesterol reductase
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(DHCR24) and 7-dehydrocholesterol reductase (DHCR7) concludes the de novo synthesis of
cholesterol(40; 41). 
Lipoprotein Dynamics and Reverse Cholesterol Transport
Very  low density  lipoprotein  cholesterol  (VLDL-C)  is  formed  from the  hepatic  pool  of
cholesterol to transport endogenously synthesised TAG to the tissues(42). Partial hydrolysis of
VLDL by LPL forms intermediate density lipoprotein (IDL), with subsequent hydrolysis of
IDL by hepatic lipase (HL) forming LDL, which acts to deliver cholesterol to the peripheral
tissue(42). VLDL-C, IDL-C and LDL-C can be removed from the circulation by hepatic LDLr,
while LDL-C can also be absorbed independently(43; 44). Reverse cholesterol transport (RCT)
transfers cholesterol from the tissues to the liver via HDL, reducing the risk of cholesterol
accumulation  and  atherosclerosis(45).  Cholesterol  can  be  effluxed  from the  tissues  by  the
receptors  ABC-A1,  and  scavenger  receptor  class  B  member  1  (SR-B1),  or  via  receptor
independent passive diffusion to nascent HDL(46;  47;  48). The incorporated cholesterol is then
esterified by lecithin-cholesterol acyltransferase (LCAT)(49). Cholesterol enters the liver either
directly, via the receptor SR-B1, or via the enzyme cholesteryl ester transfer protein (CETP).
CETP mediates  the  1:1  exchange  of  cholesterol  from HDL with  TAG from VLDL and
LDL(50). Once in the liver, cholesterol can be removed from the body.
Cholesterol Excretion
Cholesterol  can be removed from the body by two mechanisms,  directly  via  the  hepatic
ABCG5/G8 receptor  and effluxed to  the gall  bladder  or  alternatively,  cholesterol  can  be
converted  to  bile  acids  for  faecal  excretion(51;  52).  Approximately  98%  of  bile  acids  are
conjugated  to  either  taurine  or  glycine,  as  conjugation  increases  polarity,  which  reduces
passive transport from the intestinal lumen into enterocytes, and allows the movement of bile
acids  to  be  tightly  regulated,  and  under  receptor  control;  in  addition  to  improving
solubility(53). Removal of the amino acid from conjugated bile acids, by bacterial  bile salt
hydrolase (BSH), decreases reabsorption efficiency, thus unconjugated bile acids make up
98% of the 5% of bile acids that are excreted daily(54; 55). This modification is of significant
interest,  as the production of more readily excreted bile acids,  may lead to the increased
conversion  of  cholesterol  to  bile  acids  to  replace  those  lost,  in  turn  lowering  serum
cholesterol(56).
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Cholesterol and Health-span 
Intrinsic Ageing
The ageing process has been associated with an increase in both total cholesterol (TC) and
LDL-C. For instance, Ericsson et al. (1990) reported an increase in TC from 4.8mmol/L in
the young (aged 20-39 years), to 5.14mmol/L in the middle aged (aged 40-59 years), and to
5.44mmol/L in old aged (aged 60-80 years) healthy Scandinavian volunteers(57). Furthermore,
LDL-C increased  with age,  from 3.37 in  the  young,  to  3.76  in  the  middle  aged,  and to
4.05mmol/L  in  the  old  aged.  Additionally,  VLDL-C has  been observed to  either  remain
steady or increase with age, while HDL-C appears to be unaffected by the ageing process (57;
58). Abbott et al. (1993) also found gender influences the lipoprotein profile. For example,
females exhibited higher levels of LDL-C, especially in those using oestrogen hormones, and
increased  HDL-C,  whereas  VLDL-C  was  greater  in  males(58).  The  age  associated
dysregulation of cholesterol metabolism, and accumulation of LDL-C, has been associated
with  alterations  to  several  key  mechanisms,  including  cholesterol  absorption,  LDL-C
clearance, bile acid synthesis and subsequent intestinal bacterial modification (Figure 5)(5). 
Intestinal cholesterol absorption varies greatly between individuals; with estimates ranging
from 20.0  to  80.1%(58;  59).  Evidence  from murine  models  suggests  cholesterol  absorption
increases significantly with age(7). Rodent studies have demonstrated this is mediated by a
significant  increase  in  NPC1L1  in  both  the  duodenum  and  jejunum,  while  ABCG5/G8
expression is suppressed(60). It has been estimated this increase in cholesterol absorption and
concurrent reduction in efflux from enterocytes,  confers a 19-40% increase in cholesterol
absorption with age(60). Moreover, it was observed that high levels of oestrogen upregulated
NPC1L1 and ABCG5/G8 mRNA expression. Oestrogen and ageing have been reported to
enhance cholesterol  absorption via  the ERα pathway(60).  It  is  important  to  note that  these
findings have not yet been observed in humans(59).
Bile acid metabolism is also effected by the ageing process, most significantly, there is a
reduction in bile acid synthesis. Wang et al. (2002) found ageing resulted in a significantly
reduced  biliary  bile  acid  output,  from  192-211µmol/h/kg  to  124-157µmol/h/kg  in  mice.
Additionally Wang et al. (2002) demonstrated intrinsic ageing resulted in a reduction in bile
acid synthesis, with a 33.3-57.1% and 41.7-56.3% decrease in cholesterol  7α-hydroxylase
(CYP7A1) activity in male and female mice respectively, dependent on dietary and genetic
factors(7). Similarly in humans, an inverse correlation between age and CYP7A1 expression
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has been described(61). For instance, cholesterol 7α-hydroxylation rates were reduced by 50%
for individuals over 65 years, compared with individuals below 65 years of age in one Italian
cohort(62).  Bertolotti  et  al.  (1993)  estimated  by  linear  regression  analysis  a  60mg/day
(~150µmol/day)  decline  every  10  years,  in  cholesterol  undergoing  cholesterol  7α-
hydroxylation(62),  while  Einarsson  et  al.  (1985)  estimated  an  80mg/day  (200µmol/day)
reduction  over  the  same  time  period(63).  Bertolotti  et  al.  (2007)  propose  the  age-related
reduction  in  CYP7A1 expression  could  be  related  to  the  concomitant  decline  in  hepatic
nuclear factor 4 and co-activator CYP7A1 promoter binding factor/liver receptor homologue-
1 (CPF/LRH-1), mediated by the decline in growth hormone (GH) and insulin-like growth
factor (IGF)(61). 
Once  bile  acids  reach  the  small  intestine,  modification  by  digestive  microflora  occurs
influencing  enterohepatic  circulation.  Many  digestive  bacteria  produce  the  enzyme  BSH
which deconjugates bile acids, decreasing reabsorption efficiency, and enhancing excretion.
For example, Tanaka et al. (1999) reported 59 and 98% of Lactobacillus and Bifidobacteria
strains, isolated from faeces are BSH positive(64). With age there are several changes to the
gut microflora, including a decline in the number and species diversity of Lactobacillus and
Bifidobacterium(8;  65). Therefore it is possible that the age-related decline of these bacterial
species, reduces bile acid deconjugation, and in turn reduces the conversion of cholesterol to
bile acid. This may play a role in the accumulation of cholesterol with age(5).
It has also been reported, the clearance rate of LDL-C is affected by the ageing process. The
apo B-100 containing lipoproteins, LDL-C and VLDL-C are removed from the blood via
hepatic LDLr, for elimination, either by direct efflux or conversion to bile acids. Millar et al.
(1995) determined the mean LDL apo B-100 residence time was 2.42 days for younger male
adults (mean age 31±6years) and 3.46 days for older male adults (mean age 61±10years)(6).
With age, a decline in LDLr activity and/or numbers is thought to be responsible for the
reduction in LDL clearance rate and increase in residence time. The reduced conversion of
cholesterol  by  CYP7A1 may  play  a  role  in  reduction  of  LDLr.  Additionally,  proprotein
convertase  subtilisin/kexin  type  9  (PCSK9),  a  proprotein  convertase  responsible  for  the
degradation of LDLr has been correlated with age(66).  Interestingly,  PCSK9 has also been
correlated with BMI, TC, LDL-C, and TAG(67). Furthermore, Millar et al. (1995) observed,
that although VLDL apo B-100 residence time was not effected by age, the production rate of
VLDL apo B-100 was correlated with age. The age-related increase in body fat and elevated
plasma FFAs were attributed to this increase in VLDL apo B-100 production rate(6).
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Cholesterol metabolism and Diet
Herron et al. (2003) examined the effect of ~640mg/day cholesterol feeding on men aged 18-
57 years old, and determined that 37.5% of subjects behaved as hyper-responders, with an
increase of ≥0.06mmol/L in TC, while 62.5% behaved as hypo-responders, with an increase
in  TC  of  <0.05mmol/L.  Hyper-responders  exhibited  a  significant  23.0,  7.8  and  18.0%
increase in LDL-C and HDL-C, and LDL:HDL ratio respectively, whereas changes to LDL-
C, HDL-C, TG and LDL:HDL ratio were not significant for hypo-responders. Interestingly,
hyper-responders exhibited elevated LCAT and CETP activity, suggesting the upregulation
of RCT as a compensatory mechanism, to reduce the risk of atherosclerosis (68). Quintao et al.
(1971) propose tissue pools of cholesterol  may rapidly expand in response to cholesterol
feeding, even in the absence of aberrations to plasma cholesterol levels. Typically, there are 2
main mechanisms to compensate for an increase in dietary cholesterol; elevated cholesterol
excretion,  and  decreased  cholesterol  synthesis(69).  It  has  been  suggested  a  reduction  in
cholesterol  intake  should  be  considered  unnecessary  for  individuals  who  have  already
reduced SFA, and increased PUFA: SFA ratio(70). Edington et al. (1987) determined a 2-fold
increase or decrease in dietary cholesterol in participants who also reduced dietary fat with an
increased PUFA:SFA ratio had no effect on TC or LDL-C after 8 weeks(70). This is due to the
significant impact SFA had on serum LDL-C, by influencing several regulatory mechanisms.
Firstly,  it  has  been  observed  there  is  a  reduction  in  LDLr;  resulting  in  reduced  LDL-C
clearance and increased LDL-C(71). Mustad et al. (1997) demonstrated an 8 week reduction in
SFA resulted in a 10.5% increase in LDLr and subsequent 11.8% decrease in LDL-C. It has
been estimated  for every 1% increase  in  LDLr,  there is  a 0.74% reduction in  LDL-C(71).
Secondly, SFA may influence cholesterol synthesis(72). Glatz & Katan (1993) determined a
low PUFA:SFA ratio diet  resulted in increased cholesterol  synthesis, compared to a high
PUFA:SFA ratio diet (1.86mmol/day vs. 1.55mmol/day).  Additionally,  Jones et al. (1994)
demonstrated  corn  oil  increased  absolute  cholesterol  synthesis  from  13.9mg/kg/day  at
baseline,  to  21.3mg/kg/day(73).  Thirdly,  it  has  been  demonstrated  SFA  influences  the
concentration of CETP. For example,  Jansen et  al.  (2000) observed CETP concentrations
were significantly elevated by 12 and 11%, in individuals on a high SFA diet, compared with
individuals  on  the  NCEP  StepI  diet  and  MUFA  diet  respectively(74).  Additionally,  an
elevation of SFA from 8.4 to 11% decreased LCAT activity from 56 to 74nmol/ml/h, which
may result in decreased RCT and influence CVD risk(75).
Cholesterol metabolism and Disease
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The  age  related  accumulation  of  both  TC  and  LDL-C  has  been  associated  with  the
pathogenesis of several diseases(76; 77; 78). In a meta-analysis of 62 studies, a 17.5% reduction in
relative risk for all-cause mortality for every 1mmol/L decrease in TC was reported, while
each 1mmol/L decrease in LDL-C was associated with a 15.6% relative risk reduction for all-
cause mortality(79). 
CHD has been associated with significantly elevated TC, LDL-C, TAG, apo B, and Lp(a) and
reduced HDL-C and apo A-I in both American males and females(78). Gould et al. (2007)
reported a 24.5 and 29.5% reduction in relative risk for CHD related mortality and CHD
event respectively for every 1mmol/L decline in TC. Additionally, each 1mmol/L decline in
LDL-C was  associated  with  a  28.0  and  26.6% decline  in  relative  risk  for  CHD related
mortality and CHD event respectively(79). Sharrett et al. (2001) found each 1mmol/L increase
in LDL-C was associated with a relative risk for CHD of between 1.36-1.44 for males and
1.19-1.32 for females, while a 0.4mmol/L increase in HDL-C was associated with a 0.64-0.72
and 0.64-0.76 relative risk for CHD for males and females, respectively (78). Interestingly, the
decreased risk for mortality with reduced TC has been observed to decline with age. For
example,  a  meta-analysis  conducted  by  Lewington  et  al.  (2007)  concluded  a  1mmol/L
reduction in TC was associated with an ~50% reduction in IHD mortality for 40-49 year olds,
which decreased to an ~33% reduction for 50-69 year olds and ~17% for 70-89 year olds(80).
Intriguingly, several studies have described an inverse relationship between cholesterol and
mortality(81).  Lv et al.  (2015) observed a 19% decrease in relative risk for each 1mmol/L
increase in LDL-C in Chinese ≥80 year olds. Additionally, a 40% lower risk for mortality
was associated with those with abnormally high LDL-C (≥3.37 mmol/L), compared to those
with a lower plasma concentration of LDL-C(82). Similarly, Takata et al. (2014) observed a
0.8% decrease in mortality for each 1mg/dL (0.026mmol/L) increase in LDL-C in Japanese
≥80 year olds. In addition, each 1mg/dL increase in TC was associated with a 0.9% reduction
in mortality(83). 
Targeting Cholesterol Metabolism as a Therapeutic Strategy 
There are many strategies utilised in the treatment of hypercholesterolaemia. These can be
used  singularly  or  in  combination,  and  include  changes  to  diet  and  exercise  regimes,
pharmacological intervention, and dietary supplementation(9; 11; 84; 85). 
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Dietary Intervention
A reduced intake of SFA, and increase in MUFA and PUFA may be useful in maintaining a
healthy lipid profile, and reducing CHD risk(11). An 8 week reduction in SFA was observed to
reduce TC and LDL-C by 9.3 and 11.8% respectively in healthy males and females aged
between 20 and 65 years old(71). Additionally, Berry et al. (1991) reported a 12 week MUFA
or PUFA diet reduced TC by ~10 and ~16% respectively, while reducing LDL-C by 14 and
21%(86). A meta-analysis of 13,614 participants participating in diets where SFA was replaced
with PUFA, found that on average there was a 0.76mmol/L (29mg/dL) reduction in TC, and
that  each  1mmol/L  reduction  in  TC was  associated  24% reduced risk for  a  CHD event.
Moreover, each additional year of diet was related to a further 9.2% risk reduction(11). 
Additionally,  the  use  of  phytosterols  is  recommended  as  a  therapeutic  strategy  for  the
treatment  of  hypercholesterolaemia.  It  is  estimated  a  2g/day  dose  of  phytosterols  lowers
LDL-C by 10%(87). A meta-analysis of 124 studies concluded, 0.6-3.3g/day of phytosterols
reduced  LDL-C  by  6-12%,  with  stanols  and  sterols  showing  similar  LDL-C  lowering
efficacies(85).  The  effect  of  phytosterols  has  been  observed  to  taper  off  at  2-3g/day(87),
therefore  2mg/day  has  been  recommended  to  aid  in  the  treatment  of
hypercholesterolaemia(88).
Pharmacological Intervention
Lipid lowering drugs are often utilised in the treatment of CVD (Figure 6). Statins are often
recommended for those diagnosed with CVD, or those with a high risk of developing the
disease, due to their tolerability and efficacy (89). Statins act by competitively inhibiting HMG
CoA reductase,  the rate limiting enzyme of cholesterol  synthesis in order to lower serum
cholesterol, thus reducing CVD risk(90). Simivastatin reduced LDL-C by 33% after 12 weeks,
in  patients  with  a  history  of  myocardial  infarction,  while  atorvastatin  exhibited  a  49%
reduction(91). A meta-analysis of 4 trials demonstrated standard-dose statin therapy reduced
LDL-C by  22%,  to  a  mean  of  2.59mmol/L  (101mg/dL),  while  high-dose  statin  therapy
reduced LDL-C by 42%, to a mean of 1.92mmol/L (75mg/dL)(92). The standard dose therapy
was associated with a coronary death or myocardial event rate of 9.4%, whereas high dose
therapy was associated with an 8.0% event rate. Significantly, overall statin therapy resulted
in a 16% odds reduction in coronary death or myocardial infarction(92). Ridker et al. (2005)
observed that patients whose statin therapy reduced LDL-C to <70mg/dL (<1.81mmol/dL),
had a reduced rate of recurrent myocardial  infarction or death from coronary events (2.7
11
events per 100 person-years), than individuals whose statin therapy did not reach this goal
(4.0  events  per  100  person-years)(93).  However,  it  has  also  been  demonstrated  non-statin
therapy (diet, bile acid sequesterants and ileal bypass surgery) reduced CHD risk equally to
that of statins, with each 1% reduction in LDL-C corresponding to a 1% decrease in CHD
risk(10). Statins can also be used in combination with drugs such as Ezetimbibe, which targets
NPC1L1 to lower cholesterol absorption. Cannon et al.  (2015) observed that combination
therapy lowered LDL-C by a further 24% than statin therapy alone. Combination therapy also
significantly reduced myocardial infarction and ischemic stroke risk(84).
Targeting the Gut Microbiome
There is emerging evidence indicating the important role for the gut microbiome in regulating
many biological systems, including cholesterol metabolism(94;  95). Ageing is associated with
the  alteration  of  the  gut  microbiome.  These  changes  differ  between  individuals  and
populations,  as  diet,  lifestyle,  host  health  and  antibiotic  use  likely  play  a  role  in
composition(96; 97). However, it has been observed Lactobacillus and Bifidobacterium species
diversity and total count decline with age(8; 65). Supplementation with probiotics may have the
ability to partially ameliorate changes associated with ageing, such as immunosenescence,
neurodegeneration, carcinogenic transformation, and hypercholesterolaemia(98; 99). 
With regards to hypercholesterolaemia treatment, supplementation with probiotics has been
associated with a decline in TC and LDL-C(9). A meta-analysis of probiotic administration
studies  concluded  probiotic  administration  resulted  in  a  mean  6.40mg/dL  (0.17mmol/L)
reduction in TC, and 4.90mg/dL (0.13mmol/L) reduction in LDL-C. Additionally probiotics
were  observed  to  have  beneficial  effects  on  TC  and  LDL-C  for  individuals  with  high,
borderline  high,  and  normal  cholesterol  levels(9).  Probiotics  have  also  been  an  effective
treatment  strategy for individuals  with underlying conditions.  For example,  Bernini  et  al.
(2016) observed ingestion of 80ml probiotic milk containing 3.4x108 colony forming units
(CFU)/ml of Bifidobacterium lactis HN019 for 45 days, significantly lowered TC from 209 to
194mg/dL (5.40mmol/L and 5.02mmol/L), and LDL from 128.5 to 111mg/dL (3.32mmol/L
to 2.87mmol/L) in patients with metabolic syndrome, in addition to lowering BMI. Moreover,
the proinflammatory cytokines TNF-α and IL-6 were significantly reduced with probiotic
treatment(100).
There are several proposed mechanisms to explain the lipid-lowering ability of probiotics (101).
For example, some probiotics produce the bile acid deconjugating enzyme BSH, which may
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increase bile acid excretion,  and upregulate  the conversion of cholesterol  to bile  acids to
replace those lost(102). It has also been observed that probiotics increase short chain fatty acids
(SCFA), which inhibit the hepatic rate limiting enzyme in cholesterol synthesis, HMG CoA
reductase(101).  Furthermore,  there may be a  reduction in  cholesterol  absorption due to  the
assimilation and possible incorporation of cholesterol into the bacterial  cell membrane(103).
Additionally,  some bacteria  may act  by destabilising  cholesterol  micelles  resulting in  the
coprecipitation of cholesterol with deconjugated bile acids(103). 
Applying Systems Biology to our Understanding of Cholesterol Metabolism and Ageing
It  is  apparent  from our  discussion  of  cholesterol  metabolism,  that  it  is  an  exceptionally
complex  system  with  a  multitude  of  interacting  mechanisms(104;  105).  Many  of  these
mechanisms interact via positive and negative feedback regulators, the dynamics of which is
not trivial.  Our understanding of this complexity is further compounded by ageing which
alters the behaviour of these regulatory mechanisms, thus modifying the overall dynamics of
whole-body cholesterol metabolism. Moreover, changes to extrinsic factors such as diet exert
a significant influence on the overall behaviour of this system. Thus, it is imperative if we are
to  gain  a  more  in-depth  appreciation  of  cholesterol  metabolism  and  its  interaction  with
ageing, that we investigate this system in a more integrated manner. The systems biology
paradigm  contrasts  with  the  more  traditional  reductionist  approach,  commonly  used  in
nutrition research, and offers a more integrated way to study this multifaceted system(14;  106;
107).  A fundamental  element  of this  paradigm shift  is the close coupling of computational
modelling with experimental work(108; 109; 110; 111).  Our group has used computational systems
biology to investigate cholesterol metabolism and ageing(112). Firstly, we constructed a whole-
body model of cholesterol metabolism(113; 114). The model is defined by the key components
that characterise whole body cholesterol balance, namely cholesterol ingestion, excretion and
synthesis together with LDLr receptor turnover and RCT. Using  in silico experiments we
explored  the impact  of ageing on these fundamental  elements  of  cholesterol  metabolism.
Firstly, we investigated the influence of ageing on cholesterol absorption and it was found
that for every 10% increment in the rate of cholesterol absorption, there was a concomitant
increase  of  12.5  mg/dL  in  LDL-C.  The  model  also  revealed  that  increasing  cholesterol
absorption from 50% to 80% by age 65 years, resulted in a 34 mg/dL increase in plasma
LDL-C.  In  addition,  the  model  found  that  reducing  the  number  of  hepatic  LDLr  had  a
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significant impact on the system. An increase of 116 mg/dL in LDL-C was observed by 65
years  in  response  to  a  reduction  of  50%  in  their  numbers.  Thus,  emphasizing  LDLr
maintenance as a key component in maintaining cholesterol metabolism during ageing. This
model  is  coded  in  the  systems  biology  markup  language  (SBML)  and  archived  in  the
BioModels  database a  repository  for  models  encased  in  SBML  exchange  framework
(http://www.ebi.ac.uk/biomodels-main/BIOMD0000000434).  This  means  the  model  is
straightforward  to  update  and adapt,  a  feature  exploited  by other  groups working in  this
area(115). We recently implemented significant updates to the model described above for the
following  reasons(116).  The  model  was  lacking  several  key  mechanisms  which  recent
experimental evidence has stressed are central to the regulation of cholesterol metabolism.
Briefly,  these  processes  included  plasma membrane  receptors,  and  in  vivo and intestinal
microfloral enzymes. Therefore, it was deemed cogent that these 96 additional mechanisms
were incorporated into the original model(5). We found that our updated model behaved as a
hypo-responder  to  excessive  cholesterol  feeding.  Moreover,  the  model  was  utilised  to
investigate the effects of ageing coupled with three different CETP genotypes. Ageing in the
presence of a genotype conferring low CETP activity resulted in a 0.6% decrease in LDL-C
after 1000 hours. In comparison, ageing with a genotype indicative of high CETP activity,
provoked a 1.6% increase in LDL-C levels (Figure 7). Thus, our new model consolidates
experimental  findings,  which  emphasize  the  significance  of  CETP  genotypes  in  health-
span(116).
Complimenting Computational models with Simulated Digestive tracts
In order to complement our in silico studies of cholesterol metabolism, we aim to develop a
simulator of the human digestive tract. The digestive track simulator will be used to refine
and inform our computational model. One example is the simulator of the human intestinal
microbial ecosystem (SHIME) reactor, which represents the length of the human digestive
system, with several  closed reactors  used to  represent  the differing conditions  (microbial
ecosystem, pH, enzymes, etc.) of each section of the digestive tract(117). The flexible nature of
the SHIME reactor means that can be easily adapted. This may include additional reactors to
more accurately represent the human digestive tract(118; 119). Simulated digestive tracts, such as
the SHIME reactor provide a suitable test environment to supplement experimental data on
potential therapeutic strategies. For example, De Smet et al. (1998) determined administration
of Lactobacillus to pigs for 4 weeks decreased TC and LDL-C by 15 and 24%, respectively.
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Additionally,  TC and LDL-C reduced a  further  18 and 34% 3 weeks after  treatment (120).
Follow-up  experimentation  using  the  SHIME reactor  was  able  to  provide  details  of  the
intestinal  bacterial  population  and  overall  metabolic  activity  associated  with  this
treatment(118). Recently, a continuous gut adhesion model was developed using mucin-alginate
beads  to  immobilise  bacteria,  which  may  more  effectively  represent  the  gut  lining  and
intestinal  lumen.  This  system was  also  used  to  examine  bacterial  colonisation  following
probiotic  treatment(121).  The  TNO gastro-intestinal  model  (TIM)  can  be  used  to  examine
compound  absorption(122).  This  model  simulates  ingestion  of  food  and  water,  digestive
enzyme and bile salt release, peristalsis, body temperature, and transit through the stomach
and small intestine (TIM-1) and large intestine (TIM-2) under computer control. The model
can be altered to represent  a different  species,  such as a human or pig,  or can represent
varying age, such as infant, adult and older people(122). This is particularly significant for the
augmentation and refinement of our computational model. It is hoped that utilizing both these
approaches  in  tandem will  help  to  significantly  deepen  our  understanding  of  cholesterol
metabolism and its relationship with ageing. 
Discussion
The dysregulation of cholesterol metabolism accompanies the ageing process; this may play a
role  in  disease  pathogenesis.  We  have  outlined  how  the  age  related  dysregulation  of
cholesterol  metabolism  is  influenced  by  many  factors.  Specifically  we  discussed  i)  an
increase in LDL-C residence time due to reduction in LDLr and concomitant decline in LDL-
C clearance, ii) a decline in CYP7AI activity which reduces bile acid synthesis, one pathway
for cholesterol removal, iii) a reduction in digestive bacteria which modify bile acids that
reduce  reabsorption  and  promotes  excretion  and  iv)  a  potential  increase  in  cholesterol
absorption due to an increase in NPC1L1 and decrease in ABCG5/G8, as observed in murine
models. Cholesterol metabolism is also influenced by diet. For example, a meta-analysis of
67 trials revealed that soluble fibre could lower TC and LDL-C by 0.045 and 0.057mmol/L/g
soluble  fibre  respectively(123).  There  are  a  variety  of  mechanisms that  dietary  fibre  could
influence; for example, bile acid micelle formulation, fat excretion, intestinal motility, SCFA
production,  and  absorption  of  macronutrients(124;  125;  126).  Interestingly,  diet  may  not  only
impact cholesterol metabolism directly, and may also interact with the gut microbiome(127).
David et al. (2014) describe that short term changes to diet could significantly influence both
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the  microbial  community  structure  and  bacterial  gene  expression.  For  example,  a  5  day
animal based-diet significantly altered the abundance of 22 clusters, elevated faecal bile acid
concentration, and increased BSH expression(128). Evard et al. (2014) describe that high fat
feeding significantly affected 20 genera. This may have been influenced by a decline in the
antimicrobial  peptide  regenerating  islet-derived  protein  3  gamma  (Reg3g).  Interestingly,
prebiotic  treatment  increased  Reg3g  ~6-fold  within  the  colon.  Targeting  the  digestive
microbiota  with  pre-  and  probiotics  is  a  potential  avenue  for  the  treatment  of  diseases
including  hypercholesterolaemia.  For  instance,  meta-analysis  of  11  clinical  trials
demonstrated that probiotic intervention was associated with an average reduction in TC and
LDL-C  of  0.17mmol/L  and  0.22mmol/L  respectively.  Studying  these  mechanisms
underpinning  these  complex  interactions  of  intrinsic  ageing  and  diet  on  cholesterol
metabolism, can be challenging. In recent years, nutrition research has benefitted from using
computational  modelling to study the complexities associated with ageing and cholesterol
metabolism. This approach provides a meaningful framework for handling this complexity.
Modelling  enables  hypothesis  exploration,  and  allows  us  to  predict  the  behaviour  of
cholesterol metabolism over time. We used computational modelling to construct a whole
body mathematical  model of cholesterol  metabolism and its  age associated dysregulation.
Encased  within  this  template  we  incorporated  many  key  mechanisms,  including  LDLr
turnover, intestinal cholesterol absorption, and endogenous cholesterol synthesis. Using our
in silico 20 year  old,  a number of  mechanisms were explored.  By increasing cholesterol
absorption from 50% to 80% by 65 years, we were able to show that LDL-C increased by 34
mg/dL from its  baseline  value  of  100mg/dL at  20 years  of  age in  a  healthy  adult  male.
However, the key finding of the model centred on hepatic LDLr. Using the model we were
able  to  show that  by decreasing  the  activity  of  the  LDLr  to  50% by age  65  years,  this
produced a rise in LDL-C of 116mg/dL, from a base line value of 100 mg/dL at age 20 years
in a healthy male. More recently, we updated the model to include a further 96 mechanisms.
The updated model behaved as a hypo-responder to increased dietary cholesterol, whereas
SFA  feeding  elevated  LDL-C,  in  addition  to  hepatic  and  peripheral  pools  of  esterified
cholesterol. Furthermore, the age related increase in LDL-C was reduced in the presence of
low CETP activity.  In addition to exploring these aspects  of cholesterol  metabolism it  is
possible  that  computational  modelling  could  be  used  to  examine  the  role  of  the  gut
microbiome  on  host  health(129).  Moreover  computational  models  are  an  effective  way  of
complimenting simulated digestive tracts, such as the SHIME reactor which is a useful tool
for  investigating  the  microbial  community  and  metabolic  activity  of  each  section  of  the
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digestive tract in response to ingested substrates, something which is difficult to achieve  in
vivo(130).  This  is  particularly  significant  as  recent  evidence  has  indicated  that  the  gut
microbiome  could  have  a  significant  impact  heath-span  and  may  provide  a  potential
therapeutic target to treat age associated hypercholesterolaemia. 
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Figures
Figure 1 UK life expectancy by year of birth. Data from Clio-Infra(131).
Figure 2 UK population by age and gender in 1982 and 2012. Data from United Nations 
Statistics Division(132).
Figure 3 UK causes of death by age. Data from British Heart Foundation(133).
Figure 4 Modelling Overview. (1) Identify the system to model and hypothesis formation. (2)
Identify pre-existing models; using the BioModels Database, a repository for peer reviewed
models. (3) If no model of the system of interest exists: produce a network diagram. If a
model  does  exist:  download  model  and  move  to  step  5,  then  step  7.  (4)  Establish
mathematical framework. (5) Identify a suitable modelling tool; there are several available
including: COPASI, which we utilized in our updated model of cholesterol metabolism (116),
CellDesigner, Mathematica and MATLAB. (6) Obtain initial concentrations of species, rate
laws and kinetic data to construct the model. The online resources BRENDA and SABIO-RK
provide a substantial volume of kinetic data. (7) Run simulations. (8) Validate the model. (9)
Explore  the  hypotheses,  and  determine  if  the  model  accurately  represents  the  biological
system, and can be used to make predictions, or if the model needs refining. (10) Conduct
further wet laboratory experiments based upon model output. (11) Code the model in the
exchange format, Systems Biology Markup Language (SBML) and deposit in the BioModels
Database. Adapted from Mc Auley and Mooney (2015)(134).
Figure 5 Overview of age-related changes to cholesterol metabolism.
Figure 6 UK prescription drugs for cardiovascular disease. Data from British Heart 
Foundation(133).
Figure 7 Model simulation of ageing in the presence of CETP genotypes. Taken from 
Morgan et al. (2016)(116).
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